Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1Phase 1/2 1

Status

Recruiting 2Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Carcinoma, Transitional Cell 12Urinary Bladder Neoplasms 9Ureteral Neoplasms 4Urologic Neoplasms 3Urethral Neoplasms 2Neoplasm Metastasis 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Urothelial Cancer 1Urologic Diseases 1Urogenital Neoplasms 1Urogenital Diseases 1Urinary Bladder Diseases 1Triple Negative Breast Neoplasms 1Salivary Gland Neoplasms 1Peripheral Nervous System Diseases 1Penile Squamous Cell Carcinoma (PSCC) 1Neoplasms by Site 1Neoplasms 1Muscle-invasive Bladder Cancer 1Muscle Invasive Bladder Urothelial Carcinoma 1Metastatic Urothelial Cancer 1Male Urogenital Diseases 1Head and Neck Neoplasms 1Female Urogenital Diseases 1Esophageal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Hepatocellular 1Carcinoma, Adenoid Cystic 1Adenocarcinoma of the Bladder 1

Interventions

Specimen Handling 6pembrolizumab 4enfortumab vedotin 4Magnetic Resonance Spectroscopy 4Nivolumab 3Gemcitabine 3cabozantinib 2avelumab 2Ipilimumab 2Immunoglobulin G 2Disulfides 2Carboplatin 2CTLA-4 Antigen 2Biopsy 2tremelimumab 1tocilizumab 1relatlimab 1eribulin 1erdafitinib 1durvalumab 1atezolizumab 1Watchful Waiting 1Standard of Care 1Practice Guidelines as Topic 1Plasmapheresis 1Plasma Exchange 1Observation 1Lenalidomide 1Doxorubicin 1Cystoscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Ureteral Neoplasms × enfortumab vedotin × 90 days × Clear all
NCT05614739 2026-05-19

FORAGER-1

Eli Lilly and Company

Phase 1 Recruiting
535 enrolled
Genitourinary

Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral Neoplasms, Urologic Neoplasms

NCT04963153 2026-05-13

Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy

National Cancer Institute (NCI)

Phase 1 Active not recruiting
24 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT07087860 2026-05-08

RECIPE-B1

Mayo Clinic

Phase 2 Recruiting
70 enrolled
Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms

NCT03288545 2026-03-24

EV-103

Astellas Pharma Inc

Phase 1/2 Terminated
348 enrolled 1 FDA
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡